Public Policy Resources

Share

ACS CAN Comments on FDA Draft Guidance on Collection of Race and Ethnicity Data in Clinical Trials

April 24, 2024

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for Food and Drug Administration-Regulated Medical Products.

PDF icon Download Comments

Related Resources

June 12, 2026

Ve el video bilingüe de Salud America sobre ensayos clínicos.

Un video de Genentech y UT Health San Antonio explica la importancia de la participación latina en ensayos clínicos. La falta de voluntarios de este grupo dificulta el desarrollo de tratamientos efectivos para enfermedades como el cáncer, una población que sufre por esta enfermedad.

Read More

ACS CAN’s Policy Recommendations for Improving Cancer Care in Rural America

May 8, 2026

People who live in rural and remote areas have specific challenges in accessing cancer treatments and preventive services. It is estimated that up to 20% of the U.S.

Read more

ACS CAN joined by 24 groups in support of AKS safe harbor allowing financial support to trial participants

February 9, 2026

Twenty five groups joined to ask the HHS Office of Inspector General (OIG) to create a safe harbor from the Anti-Kickback Statute (AKS) allowing sponsors to financially support participants in cancer clinical trials. 

Read more